BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33624446)

  • 1. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.
    El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C
    J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
    Kieda C; El Hafny-Rahbi B; Collet G; Lamerant-Fayel N; Grillon C; Guichard A; Dulak J; Jozkowicz A; Kotlinowski J; Fylaktakidou KC; Vidal A; Auzeloux P; Miot-Noirault E; Beloeil JC; Lehn JM; Nicolau C
    J Mol Med (Berl); 2013 Jul; 91(7):883-99. PubMed ID: 23471434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates.
    Grzymajlo K; El Hafny-Rahbi B; Kieda C
    J Cell Mol Med; 2023 Mar; 27(6):879-890. PubMed ID: 36852461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
    Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
    Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
    Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
    J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
    Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA
    Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.
    Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C
    Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma.
    Sihn G; Walter T; Klein JC; Queguiner I; Iwao H; Nicolau C; Lehn JM; Corvol P; Gasc JM
    FEBS Lett; 2007 Mar; 581(5):962-6. PubMed ID: 17316624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response.
    Grgic I; Tschanz F; Borgeaud N; Gupta A; Clavien PA; Guckenberger M; Graf R; Pruschy M
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1222-1233. PubMed ID: 33587991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors.
    Krzykawska-Serda M; Szczygieł D; Gaweł S; Drzał A; Szczygieł M; Kmieć MM; Mackiewicz A; Kieda C; Elas M
    PLoS One; 2023; 18(5):e0285318. PubMed ID: 37167239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.
    Derbal-Wolfrom L; Pencreach E; Saandi T; Aprahamian M; Martin E; Greferath R; Tufa E; Choquet P; Lehn JM; Nicolau C; Duluc I; Freund JN
    Oncogene; 2013 Sep; 32(36):4313-8. PubMed ID: 23045284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate.
    Biolo A; Greferath R; Siwik DA; Qin F; Valsky E; Fylaktakidou KC; Pothukanuri S; Duarte CD; Schwarz RP; Lehn JM; Nicolau C; Colucci WS
    Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1926-9. PubMed ID: 19204295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells.
    Oknińska M; El-Hafny-Rahbi B; Paterek A; Mackiewicz U; Crola-Da Silva C; Brodaczewska K; Mączewski M; Kieda C
    J Cell Mol Med; 2020 Feb; 24(3):2272-2283. PubMed ID: 31957267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice.
    Iyengar S; Schwartz D
    Anticancer Res; 2017 Mar; 37(3):1121-1125. PubMed ID: 28314273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats.
    Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C
    Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.